Biogen Inc. investors will have another chance to prove some of their claims that the pharmaceutical company violated federal securities laws in the way it presented data about the efficacy of its expensive Alzheimer’s drug, Aduhelm.
Allie Reed is a Health Care Reporter at various prominent outlets. She covers a range of topics including social issues, lawsuits, and the impact of the Coronavirus, with a particular focus on Massachusetts and issues surrounding abortion. Allie has been featured in Our Community Now, Bloomberg Law, Los Angeles Times, BNN Bloomberg, Bloomberg News, Lincoln Times News, and the Analytics on Fire Podcast.